ARS Pharmaceuticals (SPRY) Non-Current Assets (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Non-Current Assets data on file, last reported at $42.3 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 80.47% year-over-year to $42.3 million; the trailing twelve-month figure through Mar 2026 stood at $151.1 million (up 200.0% YoY), and the FY2025 full-year result was $42.8 million, up 153.62% from the prior year.
• Non-Current Assets eased to $42.3 million in Q1 2026, from $42.8 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $51.1 million in Q1 2022 to a low of $265000.0 in Q3 2022.
• A 5-year average of $17.8 million and a median of $8.8 million in 2024 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets tumbled 99.44% in 2022 and jumped 2508.79% in 2025, its largest moves.
• Tracing SPRY's Non-Current Assets over 5 years: stood at $3.7 million in 2022, then slumped by 60.86% to $1.5 million in 2023, then surged by 1053.08% to $16.9 million in 2024, then surged by 153.62% to $42.8 million in 2025, then retreated by 0.98% to $42.3 million in 2026.
• Business Quant data shows SPRY's Non-Current Assets at $42.3 million in Q1 2026, $42.8 million in Q4 2025, and $33.9 million in Q3 2025.